Business Wire

MERZ-AESTHETICS

5.11.2020 09:32:12 CET | Business Wire | Press release

Share
Merz Aesthetics to Sponsor and Participate in First Fully Virtual Medical Aesthetics Congress AMWC Global 2020

Merz Aesthetics, a global leader in medical aesthetics, today announced the presentation of data from its medical aesthetics portfolio at the 18th edition of the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place virtually as “AMWC Global 2020, The Virtual Edition”, to be held from Thursday, November 5 to Saturday, November 7, 2020. Merz Aesthetics is an elite sponsor of the global industry congress.

“We are proud to continue our commitment to the medical aesthetics industry by sponsoring this virtual meeting. We are looking forward to sharing data on the Merz Aesthetics portfolio, engage with our customers and partners and present Merz Aesthetics in a new innovative format. It’s time to think differently to keep the momentum of the industry,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics.

In addition to the presentations listed below, Merz Aesthetics is sponsoring two symposium events to be held over the course of the meeting and led by renowned medical aesthetic experts:

“The Skin You Are In – Collagen Expert Session” to be held on Friday, November 6, 15:15h – 16:15h CET. The session will include injection videos and insights from renowned international experts:

  • Dr. Gabriela Casabona – Aesthetic Physician, Spain
  • Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
  • Professor Yana A. Yutskovskaya – Dermatologist, Russia

“conFRONT every LINE! – Upper Face Rejuvenation” to be held on Saturday, November 7, 12:30h – 13:30h CET. The session will include injection videos and insights from renowned international experts:

  • Dr. Tatjana Pavicic – Dermatologist, Germany
  • Dr. Thomas Rappl – Dermatologist, Austria

Oral Presentations
Gabriela Casabona: ‘CaHA as a Biostimulator’ (Evolution of Regenerative Aesthetics Where are We Now Session); Thursday, November 5, 13:30-15:30h CET, AMWC Stream 2*

Dr. Carla Pecora: ‘Botulinum Toxin Injection: Customized Eyebrow Reshape and Positioning, with an Individualized Approach’ (Forehead Treatment and Importance of the Eyebrow Line Session); Thursday, November 5, 16:30-18:30h CET, AMWC Stream 1*

Dr. Daria Voropai: ‘Midface Dilemmas: How Individual Approaches Require a Multiple Tissue Plane Approach and How Ultrasound, Tactile Feedback, Visual Cues Help Us to Achieve This’ (Cheeks: Fillers, Threads of Both? Session); Friday, November 6, 16:30-18:30h CET, AMWC Stream 2 *

Dr. Kate Goldie: ‘Redefining the Art of the Lip’ (Lips and Perioral Rejuvenation Session); Saturday, November 7th, 14:00-16:00h CET, AMWC Stream 2 *

Virtual E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress.

Botulinum Toxin

  • IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. Martina Kerscher, MD - Germany, Sabrina Fabi, MD – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, Dr. med – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
  • Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Type A Agents. Rashid Kazerooni – Merz North America, USA.
  • Neurotoxin Impurities: A Review of Threats to Efficacy. Je-Young Park, MD - USA, Owen Sunga, MD, MSc – Singapore, Rungsima Wanitphakdeedecha, MD, MA, MSc – Thailand, Jürgen Frevert, PhD - Germany.

Belotero®

  • Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Post-Market Study. Tatjana Pavicic, MD –Germany; Gerhard Sattler, MD – Germany, Welf Prager, MD – Germany, Tanja Fischer, MD PhD – Germany, Gerd Gauglitz, MD – Germany, Matthias Hofmann, PhD - Germany; Hanna Dersch – Germany; Shahbaz Riaz, PharmD – USA, Martina Kerscher, MD – Germany.
  • Hydration Effect of a Revitalizing CPM® Cross-Linked Hyaluronic Acid Gel Containing Glycerol. Kay Marquardt, Sabine Falk, Matthias Hofmann, Jeannette Simon, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

Radiesse®

  • CaHA microspheres remodel collagen networks leading to improved skin quality and reveal new treatment possibilities. Gabriela Casabona, MD – Spain, Bartosch Nowag, Daniela Schäfer, Davide Greco, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany
  • Combination of Calcium Hydroxylapatite Diluted with Normal Saline and Microfocused Ultrasound with Visualization for Skin Tightening. Yana Alexandrovna Yutskovskaya, MD - Russia, Anna Daniilovna Sergeeva, MD – Russia, Evgeniya Altarovna Kogan, MD PhD – Russia.*

Ultherapy®

  • Optimizing Patient Outcomes through a Customized Approach of Microfocused Ultrasound with Visualization Treatments: Consensus Guidelines from an Expert Panel. Sabrina G. Fabi, MD - USA, John Joseph, MD - USA, Julia Sevi, MD PhD - UK, Jeremy B. Green, MD - USA, Jennifer Deaver Peterson, MD – USA.

*Merz-supported Investigator Initiated Trial

About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye